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Rapid, inexpensive, and sensitive nucleic acid detection may aid point-of-care pathogen detection, 
genotyping, and disease monitoring. The RNA-guided, RNA-targeting CRISPR effector Cas13a 
(previously known as C2c2) exhibits a “collateral effect” of promiscuous RNAse activity upon 
target recognition. We combine the collateral effect of Cas13a with isothermal amplification to 
establish a CRISPR-based diagnostic (CRISPR-Dx), providing rapid DNA or RNA detection with 
attomolar sensitivity and single-base mismatch specificity. We use this Cas13a-based molecular 
detection platform, termed SHERLOCK (Specific High Sensitivity Enzymatic Reporter 
UnLOCKing), to detect specific strains of Zika and Dengue virus, distinguish pathogenic bacteria, 
genotype human DNA, and identify cell-free tumor DNA mutations. Furthermore, SHERLOCK 
reaction reagents can be lyophilized for cold-chain independence and long-term storage, and 
readily reconstituted on paper for field applications.
The ability to rapidly detect nucleic acids with high sensitivity and single-base specificity on 
a portable platform may aid in disease diagnosis and monitoring, epidemiology, and general 
laboratory tasks. Although methods exist for detecting nucleic acids (1–6), they have trade-
offs among sensitivity, specificity, simplicity, cost, and speed. Microbial Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (CRISPR-Cas) 
adaptive immune systems contain programmable endonucleases that can be leveraged for 
CRISPR-based diagnostics (CRISPR-Dx). While some Cas enzymes target DNA (7, 8), 
single effector RNA-guided RNases, such as Cas13a (previously known as C2c2) (8), can be 
reprogrammed with CRISPR RNAs (crRNAs) to provide a platform for specific RNA 
sensing (9–12). Upon recognition of its RNA target, activated Cas13a engages in “collateral” 
cleavage of nearby non-targeted RNAs (10). This crRNA-programmed collateral cleavage 
activity allows Cas13a to detect the presence of a specific RNA in vivo by triggering 
programmed cell death (10) or in vitro by nonspecific degradation of labeled RNA (10, 12). 
Here we describe SHERLOCK (Specific High Sensitivity Enzymatic Reporter 
UnLOCKing), an in vitro nucleic acid detection platform with attomolar sensitivity based on 
nucleic acid amplification and Cas13a-mediated collateral cleavage of a reporter RNA (12), 
allowing for real-time detection of the target (Fig. 1A).
To achieve robust signal detection, we identified an ortholog of Cas13a from Leptotrichia 
wadei (LwCas13a), which displays greater RNA-guided RNase activity relative to 
Leptotrichia shahii Cas13a (LshCas13a) (10) (fig. S1). LwCas13a incubated with ssRNA 
target 1 (ssRNA 1), crRNA, and reporter (quenched fluorescent RNA) (Fig. 1B) (13) yielded 
a detection sensitivity of ~50 fM (Fig. 1C, S2). Although this sensitivity is an improvement 
on previous studies with LbCas13a (12), attomolar sensitivity is required for many 
diagnostic applications (14–16). We therefore explored combining Cas13a-based detection 
with different isothermal amplification steps (fig. S3, S4A) (17, 18). Of the methods 
explored, recombinase polymerase amplification (RPA) (18) afforded the greatest sensitivity 
and can be coupled with T7 transcription to convert amplified DNA to RNA for subsequent 
detection by LwCas13a. We refer to this combination of amplification by RPA, T7 RNA 
polymerase transcription of amplified DNA to RNA, and detection of target RNA by Cas13a 
collateral RNA cleavage-mediated release of reporter signal as SHERLOCK.
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We first determined the sensitivity of SHERLOCK for detection of RNA (when coupled 
with reverse transcription) or DNA targets. We achieved single molecule sensitivity for both 
RNA and DNA, as verified by digital-droplet PCR (ddPCR) (Fig. 1C, D, S4B, C). Attomolar 
sensitivity was maintained when we combined all SHERLOCK components in a single 
reaction, demonstrating the viability of this platform as a point-of-care (POC) diagnostic 
(fig. S4D). SHERLOCK has similar levels of sensitivity as ddPCR and quantitative PCR 
(qPCR), two established sensitive nucleic acid detection approaches, whereas RPA alone 
was not sensitive enough to detect low levels of target (fig. S5A–D). Moreover, SHERLOCK 
shows less variation than ddPCR, qPCR, and RPA, as measured by the coefficient of 
variation across replicates (fig. S5E–F).
We next examined whether SHERLOCK would be effective in infectious disease 
applications that require high sensitivity. We produced lentiviruses harboring genome 
fragments of either Zika virus (ZIKV) or the related flavivirus Dengue (DENV) (19) (Fig. 
2A). SHERLOCK detected viral particles down to 2 aM and could discriminate between 
ZIKV and DENV (Fig. 2B). To explore the potential use of SHERLOCK in the field with 
paper-spotting and lyophilization (1), we first demonstrated that Cas13a-crRNA complexes 
lyophilized and subsequently rehydrated (20) could detect 20 fM of non-amplified ssRNA 1 
(fig. S6A) and that target detection was also possible on glass fiber paper (fig. S6B). The 
other components of SHERLOCK are also amenable to freeze-drying: RPA is provided as a 
lyophilized reagent at ambient temperature, and we previously demonstrated that T7 
polymerase tolerates freeze-drying (2). In combination, freeze-drying and paper-spotting the 
Cas13a detection reaction resulted in comparable levels of sensitive detection of ssRNA 1 as 
aqueous reactions (fig. S6C–E). Although paper-spotting and lyophilization slightly reduced 
the absolute signal of the readout, SHERLOCK (Fig. 2C) could readily detect mock ZIKV 
virus at concentrations as low as 20 aM (Fig. 2D).
SHERLOCK is also able to detect ZIKV in clinical isolates (serum, urine, or saliva) where 
titers can be as low as 2 × 103 copies/mL (3.2 aM) (21). ZIKV RNA extracted from patient 
serum or urine samples and reverse transcribed into cDNA (Fig. 2E) could be detected at 
concentrations down to 1.25 × 103 copies/mL (2.1 aM), as verified by qPCR (Fig. 2F). 
Furthermore, the signal from patient samples was predictive of ZIKV RNA copy number 
and could be used to predict viral load (Fig. S6F). To simulate sample detection without 
nucleic acid purification, we measured detection of ssRNA 1 spiked into human serum, and 
found that Cas13a could detect RNA in reactions containing as much as 2% serum (fig. 
S6G).
Another important epidemiological application for CRISPR-dx is the identification of 
bacterial pathogens and detection of specific bacterial genes. We targeted the 16S rRNA 
gene V3 region, where conserved flanking regions allow universal RPA primers to be used 
across bacterial species and the variable internal region allows for differentiation of species. 
In a panel of five possible targeting crRNAs for different pathogenic strains and gDNA 
isolated from E. coli and Pseudomonas aeruginosa (Fig. 2G), SHERLOCK correctly 
genotyped strains and showed low cross-reactivity (Fig. 2H). Additionally, we were able to 
use SHERLOCK to distinguish between clinical isolates of Klebsiella pneumoniae with two 
Gootenberg et al. Page 3
Science. Author manuscript; available in PMC 2017 July 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
different resistance genes: Klebsiella pneumoniae carbapenemase (KPC) and New Delhi 
metallo-beta-lactamase 1 (NDM-1) (22) (fig. S7).
To increase the specificity of SHERLOCK, we introduced synthetic mismatches in the 
crRNA:target duplex that enable LwCas13a to discriminate between targets that differ by a 
single-base mismatch (fig. S8A, B). We designed multiple crRNAs with synthetic 
mismatches in the spacer sequences to detect either the African or American strains of ZIKV 
(Fig. 3A, B) and strain 1 or 3 of DENV (Fig. 3C, D). Synthetic mismatch crRNAs detected 
their corresponding strains with significantly higher signal (two-tailed Student t-test; p < 
0.01) than the off-target strain, allowing for robust strain discrimination based off single 
mismatches (Fig. 3B, D, S8C). Further characterization revealed that Cas13a detection 
achieves maximal specificity while maintaining on-target sensitivity when a mutation is in 
position 3 of the spacer and the synthetic mismatch is in position 5 (fig. S9 and S10).
The ability to detect single-base differences opens the opportunity of using SHERLOCK for 
rapid human genotyping. We chose five loci spanning a range of health-related single-
nucleotide polymorphisms (SNPs) (Table S1) and benchmarked SHERLOCK detection 
using 23andMe genotyping data as the gold standard at these SNPs (23) (Fig. 4A). We 
collected saliva from four human subjects with diverse genotypes across the loci of interest, 
and extracted genomic DNA either through column purification or direct heating for five 
minutes (20). SHERLOCK distinguished alleles with high significance and with enough 
specificity to infer both homozygous and heterozygous genotypes (Fig. 4B, S11, S12).
Finally, we sought to determine if SHERLOCK could detect low frequency cancer mutations 
in cell free (cf) DNA fragments, which is challenging because of the high levels of wild-type 
DNA in patient blood (24–26). We first found that SHERLOCK could detect ssDNA 1 at 
attomolar concentrations diluted in a background of genomic DNA (fig. S13A). Next, we 
found that SHERLOCK was also able to detect single nucleotide polymorphism (SNP)-
containing alleles (fig. S13B, C) at levels as low as 0.1% of background DNA, which is in 
the clinically relevant range. We then demonstrated that SHERLOCK could detect two 
different cancer mutations, EGFR L858R and BRAF V600E, in mock cfDNA samples with 
allelic fractions as low as 0.1% (Fig. 4C–F) (20).
The SHERLOCK platform lends itself to further applications including (i) general 
RNA/DNA quantitation in lieu of specific qPCR assays, such as TaqMan, (ii) rapid, 
multiplexed RNA expression detection, and (iii) other sensitive detection applications, such 
as detection of nucleic acid contamination. Additionally, Cas13a could potentially detect 
transcripts within biological settings and track allele-specific expression of transcripts or 
disease-associated mutations in live cells. We have shown that SHERLOCK is a versatile, 
robust method to detect RNA and DNA, suitable for rapid diagnoses including infectious 
disease applications and sensitive genotyping. A SHERLOCK paper test can be redesigned 
and synthesized in a matter of days for as low as $0.61/test (Table S2) with confidence, as 
almost every crRNA tested resulted in high sensitivity and specificity. These qualities 
highlight the power of CRISPR-Dx and open new avenues for rapid, robust and sensitive 
detection of biological molecules.
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Figure 1. SHERLOCK is capable of single-molecule nucleic acid detection
(A) Schematic of SHERLOCK.
(B) Schematic of ssRNA target detected via the Cas13a collateral detection. The target site is 
highlighted in blue.
(C) Cas13a detection of RNA with RPA amplification (SHERLOCK) can detect ssRNA 
target at concentrations down to ~2 aM, more sensitive than Cas13a alone. (n=4 technical 
replicates; bars represent mean ± s.e.m.)
(D) SHERLOCK is also capable of single-molecule DNA detection. (n=4 technical 
replicates; bars represent mean ± s.e.m.)
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Figure 2. Cas13a detection can be used to sense viral and bacterial pathogens
(A) Schematic of ZIKV RNA detection by SHERLOCK.
(B) SHERLOCK is capable of highly sensitive detection of the ZIKV lentiviral particles. 
(n=4 technical replicates, two-tailed Student t-test; ****, p < 0.0001; bars represent mean ± 
s.e.m.; n.d., not detected)
(C) Schematic of ZIKV RNA detection with freeze-dried Cas13a on paper
(D) Paper-based SHERLOCK is capable of highly sensitive detection of ZIKV lentiviral 
particles. (n=4 technical replicates, two-tailed Student t-test; **, p < 0.01; ****, p < 0.0001; 
bars represent mean ± s.e.m.)
(E) Schematic of SHERLOCK detection of ZIKV RNA isolated from human clinical 
samples.
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(F) SHERLOCK is capable of highly sensitive detection of human ZIKV-positive serum (S) 
or urine (U) samples. Approximate concentrations of ZIKV RNA shown were determined by 
qPCR. (n=4 technical replicates, two-tailed Student t-test; ****, p < 0.0001; bars represent 
mean ± s.e.m.; n.d., not detected)
(G) Schematic of using SHERLOCK to distinguish bacterial strains using a universal 16S 
rRNA gene V3 RPA primer set.
(H) SHERLOCK achieves sensitive and specific detection of E. coli or P. aeruginosa gDNA. 
(n=4 technical replicates, two-tailed Student t-test; *, p < 0.05; **, p < 0.01; ***, p < 0.001; 
****, p < 0.0001; bars represent mean ± s.e.m.). Ec, Escherichia coli; Kp, Klebsiella 
pneumoniae; Pa, Pseudomonas aeruginosa; Mt, Mycobacterium tuberculosis; Sa, 
Staphylococcus aureus.
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Figure 3. Cas13a detection can discriminate between similar viral strains
(A) Schematic of ZIKV strain target regions and the crRNA sequences used for detection. 
SNPs in the target are highlighted red or blue and synthetic mismatches in the guide 
sequence are colored red.
(B) Highly specific detection of strain SNPs allows for the differentiation of ZIKV African 
versus American RNA targets using Cas13a. (n=2 technical replicates, two-tailed Student t-
test; **, p < 0.01; ***, p < 0.001; bars represent mean ± s.e.m.)
(C) Schematic of DENV strain target regions and the crRNA sequences used for detection. 
SNPs in the target are highlighted red or blue and synthetic mismatches in the guide 
sequence are colored red.
(D) Highly specific detection of strain SNPs allows for the differentiation of DENV strain 1 
versus strain 3 RNA targets using Cas13a. (n=2 technical replicates, two-tailed Student t-
test; *, p < 0.05; **, p < 0.01; ***, p < 0.001; bars represent mean ± s.e.m.)
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Figure 4. SHERLOCK can discriminate SNPs for human genotyping and cell-free allele DNA 
detection
(A) Circos plot showing location of human SNPs detected with SHERLOCK.
(B) SHERLOCK can correctly genotype four different individuals at four different SNP sites 
in the human genome. The genotypes for each individual and identities of allele-sensing 
crRNAs are annotated below each plot. (n=4 technical replicates, two-tailed Student t-test; *, 
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; bars represent mean ± s.e.m.)
(C) Schematic of cell-free DNA detection of cancer mutations using SHERLOCK.
(D) Sequences of two genomic loci assayed for cancer mutations in cell-free DNA. Shown 
are the target genomic sequence with the SNP highlighted in blue and the mutant/wild-type 
sensing crRNA sequences with synthetic mismatches colored in red.
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(E,F) Cas13a can detect the mutant minor allele in mock cell-free DNA samples for the 
EGFR L858R (E) or the BRAF V600E (F) minor allele. (n=4 technical replicates, two-tailed 
Student t-test; *, p < 0.05; **, p < 0.01; ****, p < 0.0001; bars represent mean ± s.e.m.)
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